Potential Impact of Postoperative Early Complications on the Timing of Adjuvant Chemotherapy in Patients Undergoing Radical Cystectomy: A High-Volume Tertiary Cancer Center Experience

Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 2003, Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis, Lancet, 361, 1927, 10.1016/S0140-6736(03)13580-5 Winquist, 2004, Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis, J Urol, 171, 561, 10.1097/01.ju.0000090967.08622.33 Herr, 2007, Defining optimal therapy for muscle invasive bladder cancer, J Urol, 177, 437, 10.1016/j.juro.2006.09.027 Kassouf, 2007, P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors, Eur Urol, 52, 769, 10.1016/j.eururo.2007.03.086 Schrag, 2005, Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population, Urology, 65, 1118, 10.1016/j.urology.2004.12.029 David, 2007, Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the national cancer data base, J Urol, 178, 451, 10.1016/j.juro.2007.03.101 Lehmann, 2002, Chemotherapy in the post-MVAC era: the case for adjuvant chemotherapy, World J Urol, 20, 144, 10.1007/s00345-002-0252-9 Sonpavde, 2006, Perioperative chemotherapy for bladder cancer, Crit Rev Oncol/Hematol, 57, 133, 10.1016/j.critrevonc.2005.05.004 Raghavan, 2002, Surgery and adjunctive chemotherapy for invasive bladder cancer, Surg Oncol, 11, 55, 10.1016/S0960-7404(02)00007-5 Millikan, 2001, Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC, J Clin Oncol, 19, 4005, 10.1200/JCO.2001.19.20.4005 Konety, 2006, Complications after radical cystectomy: analysis of population-based data, Urology, 68, 58, 10.1016/j.urology.2006.01.051 Jaques, 2004, Measuring morbidity, Ann Surg, 240, 214, 10.1097/01.sla.0000133124.62619.1f Martin, 2002, Quality of complication reporting in the surgical literature, Ann Surg, 235, 803, 10.1097/00000658-200206000-00007 Donat, 2007, Standards for surgical complication reporting in urologic oncology: time for a change, Urology, 69, 221, 10.1016/j.urology.2006.09.056 Miller, 2006, Comparing performance of morbidity and mortality conference and national surgical quality improvement program for detection of complications after urologic surgery, Urology, 68, 931, 10.1016/j.urology.2006.06.018 Hollenbeck, 2005, Identifying risk factors for potentially avoidable complications following radical cystectomy, J Urol, 174, 1231, 10.1097/01.ju.0000173923.35338.99 Hollenbeck, 2006, The effects of adjusting for case mix on mortality and length of stay following radical cystectomy, J Urol, 176, 1363, 10.1016/j.juro.2006.06.015 Trotti, 2003, CTCAE v. 3.0: development of a comprehensive grading system for adverse events of cancer treatment, Semin Radiat Oncol, 13, 176, 10.1016/S1053-4296(03)00031-6 Loehrer, 1992, A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study, J Clin Oncol, 10, 1066, 10.1200/JCO.1992.10.7.1066 Logothetis, 1990, A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors, J Clin Oncol, 8, 1050, 10.1200/JCO.1990.8.6.1050 Saxman, 1997, Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial cancer: a cooperative group study, J Clin Oncol, 15, 2564, 10.1200/JCO.1997.15.7.2564 Von der Maase, 2000, Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study, J Clin Oncol, 18, 3068, 10.1200/JCO.2000.18.17.3068 Dash, 2006, Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder, Cancer, 107, 506, 10.1002/cncr.22031 Raj, 2006, Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin based chemotherapy in bladder cancer, J Clin Oncol, 24, 3095, 10.1200/JCO.2005.04.3091